$23MSeries B, 7 July 2025
Funds complete a European feasibility study and start US clinical trials after FDA Breakthrough Device Designation.
- Amount
- $23M
- Stage
- Series B
- Announced
- 7 July 2025
- Lead
- Pitango HealthTech
- Other investors
- Undisclosed global strategic healthcare partner, EIC Fund, Peregrine Ventures
- Use of funds
- Funds complete a European feasibility study and start US clinical trials after FDA Breakthrough Device Designation.
- Checked
- Announced by the company
- Sources
- Restore Medical raises $23M Series B prnewswire.com
Restore Medical raises $23M Series B pulse2.com